Author Archives: Mark Senak

AdComm Drop-off in 2019 – FDA Consults Fewer Experts in 2019

The system of FDA Advisory Committees is in place so that when FDA needs advice – either on policy development, reviewing an issue with an already approved medicine, or regarding new drug approvals – the agency has a lot of … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

CBD and FDA – Where Are We?

Last week FDA and FTC jointly issued a warning letter to a seller of CBD products in Florida – the seventh such warning letter of the year. The letter took issue with the manufactuer’s marketing practices related to multiple products … Continue reading

Posted in CBD, FDA Policy | Comments Off on CBD and FDA – Where Are We?

Update on FDA Approvals for 2019

Last year new molecular entities (NMEs) were approved by FDA at a record clip, surpassing the prior record of 45 that was set in 2015. As we begin the final quarter of hte year, this is a good time to … Continue reading

Posted in Uncategorized | Comments Off on Update on FDA Approvals for 2019

Enforcement Update – FDA OPDP Sends Two More Letters

For those who like to keep up on the activity of the Office of Prescription Drug Promotion (OPDP) here is an update. While not shaping up to be another big year of enforcement, there has been a bit of activity … Continue reading

Posted in Warning Letters | Comments Off on Enforcement Update – FDA OPDP Sends Two More Letters

FDA OPDP Research – A Foggy Window into Future Thinking on Digital Media

When one thinks of FDA’s Office of Prescription Drug Promotion (OPDP) there is a likely tendency to think of the regulatory action letters – Warning Letters or Untitled Letters -issued by that office to pharmaceutical companies about their promotional communications. … Continue reading

Posted in New and Social Media | Tagged , , | Comments Off on FDA OPDP Research – A Foggy Window into Future Thinking on Digital Media